Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448

Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

R F Hector 1, E Yee 1
PMCID: PMC171613  PMID: 2159257

Abstract

The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis. Overall, Bay R 3783 was comparable or slightly superior to fluconazole and markedly superior to itraconazole and ketoconazole in both survival and short-term organ load experiments in models of candidiasis and cryptococcosis but was less effective than amphotericin B. Of the antifungal agents tested, only Bay R 3783 and itraconazole showed any efficacy in the model of pulmonary aspergillosis.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arndt C. A., Walsh T. J., McCully C. L., Balis F. M., Pizzo P. A., Poplack D. G. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis. 1988 Jan;157(1):178–180. doi: 10.1093/infdis/157.1.178. [DOI] [PubMed] [Google Scholar]
  2. Berg D., Regel E., Harenberg H. E., Plempel M. Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneimittelforschung. 1984;34(2):139–146. [PubMed] [Google Scholar]
  3. Bloch B., Barnard P. G., Burger G. D., Meyer J. S., Parkes J. R., Smythe E. Itraconazole in the treatment of acute vaginal candidiasis. S Afr Med J. 1988 Feb 6;73(3):172–173. [PubMed] [Google Scholar]
  4. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S57–S63. doi: 10.1093/clinids/9.supplement_1.s57. [DOI] [PubMed] [Google Scholar]
  5. Cauwenbergh G., De Doncker P., Stoops K., De Dier A. M., Goyvaerts H., Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S146–S152. doi: 10.1093/clinids/9.supplement_1.s146. [DOI] [PubMed] [Google Scholar]
  6. Cauwenbergh G., Degreef H., Heykants J., Woestenborghs R., Van Rooy P., Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):263–268. doi: 10.1016/s0190-9622(88)70037-7. [DOI] [PubMed] [Google Scholar]
  7. Dismukes W. E. Cryptococcal meningitis in patients with AIDS. J Infect Dis. 1988 Apr;157(4):624–628. doi: 10.1093/infdis/157.4.624. [DOI] [PubMed] [Google Scholar]
  8. Dupont B., Drouhet E. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S71–S76. doi: 10.1093/clinids/9.supplement_1.s71. [DOI] [PubMed] [Google Scholar]
  9. Foulds G., Brennan D. R., Wajszczuk C., Catanzaro A., Garg D. C., Knopf W., Rinaldi M., Weidler D. J. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol. 1988 Apr;28(4):363–366. doi: 10.1002/j.1552-4604.1988.tb03159.x. [DOI] [PubMed] [Google Scholar]
  10. Ganer A., Arathoon E., Stevens D. A. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S77–S86. doi: 10.1093/clinids/9.supplement_1.s77. [DOI] [PubMed] [Google Scholar]
  11. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  12. Graybill J. R., Ahrens J. R 51211 (itraconazole) therapy of murine cryptococcosis. Sabouraudia. 1984;22(6):445–453. doi: 10.1080/00362178485380721. [DOI] [PubMed] [Google Scholar]
  13. Hanger D. P., Jevons S., Shaw J. T. Fluconazole and testosterone: in vivo and in vitro studies. Antimicrob Agents Chemother. 1988 May;32(5):646–648. doi: 10.1128/aac.32.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hector R. F., Domer J. E. Mammary gland contamination as a means of establishing long-term gastrointestinal colonization of infant mice with Candida albicans. Infect Immun. 1982 Nov;38(2):788–790. doi: 10.1128/iai.38.2.788-790.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Heyward W. L., Curran J. W. The epidemiology of AIDS in the U.S. Sci Am. 1988 Oct;259(4):72–81. doi: 10.1038/scientificamerican1088-72. [DOI] [PubMed] [Google Scholar]
  16. Hughes C. E., Bennett R. L., Tuna I. C., Beggs W. H. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother. 1988 Feb;32(2):209–212. doi: 10.1128/aac.32.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Larosa E., Cauwenbergh G., Cilli P., Woestenborghs R., Heykants J. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol. 1986 Oct;23(1-2):85–89. doi: 10.1016/0028-2243(86)90109-7. [DOI] [PubMed] [Google Scholar]
  18. Longman L. P., Martin M. V. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit. J Antimicrob Chemother. 1987 Nov;20(5):719–724. doi: 10.1093/jac/20.5.719. [DOI] [PubMed] [Google Scholar]
  19. Marriott M. S. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol. 1980 Mar;117(1):253–255. doi: 10.1099/00221287-117-1-253. [DOI] [PubMed] [Google Scholar]
  20. Negroni R., Palmieri O., Koren F., Tiraboschi I. N., Galimberti R. L. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S47–S50. doi: 10.1093/clinids/9.supplement_1.s47. [DOI] [PubMed] [Google Scholar]
  21. Palou de Fernandez E., Patino M. M., Graybill J. R., Tarbit M. H. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. doi: 10.1093/jac/18.2.261. [DOI] [PubMed] [Google Scholar]
  22. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Phillips P., Graybill J. R., Fetchick R., Dunn J. F. Adrenal response to corticotropin during therapy with itraconazole. Antimicrob Agents Chemother. 1987 Apr;31(4):647–649. doi: 10.1128/aac.31.4.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Restrepo A., Gomez I., Robledo J., Patiño M. M., Cano L. E. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S51–S56. doi: 10.1093/clinids/9.supplement_1.s51. [DOI] [PubMed] [Google Scholar]
  25. Sobel J. D., Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Aug;26(2):266–267. doi: 10.1128/aac.26.2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stern J. J., Hartman B. J., Sharkey P., Rowland V., Squires K. E., Murray H. W., Graybill J. R. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med. 1988 Oct;85(4):477–480. doi: 10.1016/s0002-9343(88)80081-0. [DOI] [PubMed] [Google Scholar]
  27. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. doi: 10.1016/s0002-9343(88)80082-2. [DOI] [PubMed] [Google Scholar]
  28. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tucker R. M., Williams P. L., Arathoon E. G., Levine B. E., Hartstein A. I., Hanson L. H., Stevens D. A. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother. 1988 Mar;32(3):369–373. doi: 10.1128/aac.32.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Van Cauteren H., Heykants J., De Coster R., Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S43–S46. doi: 10.1093/clinids/9.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  31. Van t Wout J. W., Mattie H., van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother. 1989 Feb;33(2):147–151. doi: 10.1128/aac.33.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walsh T. J. Recent advances in the treatment of systemic fungal infections. Methods Find Exp Clin Pharmacol. 1987 Nov;9(11):769–778. [PubMed] [Google Scholar]
  33. Yozwiak M. L., Galgiani J. N. Itraconazole treatment of experimental systemic candidiasis in male rats. J Med Vet Mycol. 1987 Apr;25(2):125–126. doi: 10.1080/02681218780000171. [DOI] [PubMed] [Google Scholar]
  34. de Gans J., Eeftinck Schattenkerk J. K., van Ketel R. J. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):339–339. doi: 10.1136/bmj.296.6618.339. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES